ARTICLE | Product Development
U.K. government backs Oxford’s adaptive trial for COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 4, 2020 12:28 AM UTC
The U.K. government is backing the University of Oxford’s adaptive Phase II/III RECOVERY trial evaluating at least three therapies to treat COVID-19. The Department of Health and Social Care (DHSC) said the study will be the world’s largest randomized clinical study for the novel coronavirus.
The trial is testing antiviral combination lopinavir/ritonavir, which AbbVie Inc. (NYSE:ABBV) markets as Kaletra to treat HIV infection, the anti-inflammatory steroid dexamethasone and antimalarial drug hydroxychloroquine; patients will receive standard of care plus one of the study drugs, or standard of care alone...